Following the Trump Administration’s mandate to cut $2.6 billion in NIH contracts, the Women’s Health Initiative shares HHS will close its regional centers in September.

Pooled data demonstrated elinzanetant's efficacy overall and across BMI and smoking status subgroups. | Image credit: Monkey Business - stock.adobe.com

Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status

By Rose McNulty

April 17th 2025

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.

The meta-analysis showed that participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin. | Image credit: highwaystarz - stock.adobe.com

Elinzanetant Shows Promise for Menopausal Symptom Relief

By Rose McNulty

April 10th 2025

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin in a new meta-analysis.

Mother holding newborn baby | Image Credit: kieferpix - stock.adobe.com

World Health Day 2025 Focuses on Improving Global Maternal, Infant Health

By Brooke McCormick

April 7th 2025

World Health Day 2025 highlights the importance of improving maternal and newborn health, emphasizing the need for quality care and investment in regions facing high mortality rates.

Woman holding heart. | Image credit: Ton Photographer4289 – stock.adobe.com

5 New Heart Health Findings Released Before ACC.25 That Women Need to Know

By Hayden E. Klein

March 28th 2025

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, elevated heart failure risk after ovary removal, and more.

...

5 6 7 8 9

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions